06826 HAOHAI BIOTEC
- 30.600
- 0.0000.00%
HAOHAI BIOTEC News
Haohai Biotec (06826.HK) spent 2.8591 million yuan on July 23 to repurchase 0.047 million A shares.
On July 23, Gelunhui reported that Haohai Biotech (06826.HK) announced the repurchase of 0.047 million A-shares at a cost of 2.8591 million RMB on July 23, 2024, with a repurchase price of 60.09-61.54 RMB per share.
HKEX Stock Market Live | Ec Healthcare (02138) fell more than 6%, leading the decline in the medical beauty concept. The demand for medical beauty is temporarily under pressure, and the growth in the second quarter is slightly under pressure.
Aesthetic medicine stocks collectively declined, as of press time, ec healthcare (02138) fell by 5.45%, at HKD 1.04; shanghai haohai biological technology (06826) fell by 4.56%, at HKD 30.35; sisram med (01696) fell by 3.69%, at HKD 3.13.
haohai biotec (06826.HK) repurchased 0.039 million shares on July 22 for a total of 2.4441 million yuan.
On July 22, Gelunhui announced that Haohai Biotech (06826.HK) will spend 2.4441 million yuan to repurchase 0.039 million shares on July 22, 2024, with a repurchase price of 62.27-62.9 yuan per share.
Aesthetic medicine stocks are under pressure, and Sisram Medical (01696) fell by 4.02%. Daiwa expects macro and policy factors to suppress the growth of cosmetic medicine companies in the second half of the year.
Aesthetic medicine concept stocks are under pressure, with Sisram Med (01696) falling 4.02%, Haohai Biotech (06826) falling 2.18%, Perfect Medical (01830) falling 1.92%, and Rui'er Group (06639) falling 1.39%. On the news side, Morgan Stanley's report pointed out that under the sustained anti-corruption factor in the mainland, the market is expected to have weak second-quarter performance of medical technology companies. Investors are concerned about the timing and scale of the upcoming central government's fiscal stimulus plan, which sets expectations for medical technology stocks for the second half of this year and next year. Meanwhile, macro and policy aspects
Haohai biotec (06826.HK) repurchased 0.016 million A-shares on July 19th for a total of 0.9836 million yuan.
On July 19th, Geelonghui reported that Haohai biotec (06826.HK) announced that it will spend 0.9836 million yuan to repurchase 0.016 million shares on July 19, 2024, at a repurchase price of 60.58-61.7 yuan per share.
On July 18th, haohai biotec (06826.HK) spent 4.5041 million yuan to repurchase 0.074 million shares.
On July 18th, Gelonhui announced that Haohai Biotec (06826.HK) will buy back 0.074 million shares for a total of 4.5041 million yuan on July 18, 2024. The repurchase price is between 60.67-61 yuan per share.
Haohai Biotech (06826) spent about 2.1525 million yuan on July 17 to repurchase 0.036 million A shares.
Haohai biotec (06826) announced that on July 17, 2024, it will spend about 2.1525 million yuan to repurchase 3....
On July 15th, haohai biotec (06826.HK) spent HKD 0.39 million to buy back 0.012 million shares.
On July 15th, Gelonhui reported that haohai biotec (06826.HK) repurchased 0.012 million shares at a cost of HKD 0.39 million on July 15th, 2024, with a repurchase price per share of HKD 32.25-32.8.
Haohai biotec (06826) spent HKD 1.2574 million to repurchase 0.0379 million shares on July 12th.
Zhongtong Finance and Economics APP announcement, haohai biotec (06826) announced that the company will spend 1.2574 million Hong Kong dollars to repurchase 0.0379 million shares on July 12, 2024.
Haohai Biological Technology's Unit Gets Nod for Marketing of Amino Acid Cross-Linking Agent
Haohai Biotec (06826.HK) spent 1.4527 million Hong Kong dollars to repurchase 0.044 million shares on July 11th.
On July 11, Gelonhui reported that Haohai Biotech (06826.HK) announced it will buy back 0.044 million shares at a cost of 1.4527 million Hong Kong dollars on July 11, 2024, at a buyback price of 32.75-33.2 Hong Kong dollars per share.
Haohai Biotec (06826.HK) spent HKD 1.7493 million on July 10th to repurchase 0.0534 million shares.
On July 10th, Gelonhui announced that haohai biotec (06826.HK) will repurchase 0.0534 million shares at a cost of HKD 1.7493 million on July 10th, 2024, with a repurchase price of HKD 32.5-33 per share.
Tracking Hong Kong stocks | Rise of domestic cosmetics in the market, institutions are bullish on top companies' penetration rate improvement (attached concept stocks).
Cosmetics lead the domestic industry growth, with market share continuing to rise.
Haohai biotec (06826.HK) bought 0.0648 million shares with a cost of HKD 2.132 million on July 9th.
On July 9th, Gelonhui reported that haohai biotec (06826.HK) will spend HKD 2.132 million to repurchase 0.0648 million shares on July 9, 2024, with a repurchase price of HKD 32.65-33.15 per share.
On July 8th, haohai biotec (06826.HK) spent HKD 0.8881 million to repurchase 0.0272 million shares.
On July 8th, Gelon Hui reported that Haohai Biotech (06826.HK) would repurchase 0.0272 million shares, with a cost of 0.8881 million Hong Kong dollars on July 8th, 2024. The repurchase price per share is between 32.4-32.95 Hong Kong dollars.
Intelligent Hong Kong Stock Buyback Statistics | July 8
According to the data from Zhitong Finance APP, Vstecs (00856), Mobi Dev (00947), Cafe de Coral H (00341), Wing On International (00289), Haohai Bioteche (06826), Somerley Cap (08439), Tenfu (06868), Bank of E Asia (00023), Gme Group (08188), Simcere Pharma (02096), Tencent (00700), Zero2ipo (01945), Swire Pacific B (00087), Meinian Onehealth Healthcare Holdings (06667), and Yidu Tech (00257) are listed.
On July 5, haohai biotec (06826.HK) spent HKD 1.383 million to repurchase 0.0427 million shares.
On July 5th, Gelonhui announced that Hao Hai Biotech (06826.HK) spent 1.383 million Hong Kong dollars to repurchase 0.0427 million shares on July 5th, 2024, with a repurchase price of 31.75-32.8 Hong Kong dollars per share.
Intelligent Hong Kong stock repurchase statistics | July 5th
According to the data from Zhitong Finance APP, Somerley Cap (08439), VSTEC (00856), Mobi Dev (00947), Cafe de Coral H (00341), Skyworth Group (00751), Simcere Pharma (02096), Haohai Biotech (06826), Shoucheng (00697), Yidu (International Holdings) (00259), Zero2ipo (01945), Tsaker NE (01986), Tencent (00700), Tenfu (06868), Hang Seng Bank (00011), Zhou Hei Ya (01458), and Bairong.
BOC International: Continued prosperity of upstream medical beauty manufacturers opens up space for external expansion.
According to the research reports released by BOC International, the performance of leading medical and aesthetic companies is still maintaining good growth, and the average product price has not shown any price reduction pressure. The constantly enriched product matrix is expected to bring growth in the future.
Haohai Biotec (06826.HK) spent HKD 171,720 on July 4th to repurchase 53,200 shares.
On July 4th, Gelunhui reported that haohai biotec (06826.HK) spent HKD 1.7172 million to repurchase 53,200 shares at a repurchase price of HKD 31.9-32.8 per share on July 4, 2024.
Analysis
Price Target
No Data
